Humatica, a private equity specialist adviser for portfolio organisational effectiveness, has advised private equity firm Intermediate Capital Group (ICG) on its investment in Lucid Group
Founded in 2007, Lucid Group is a strategic healthcare communications company committed to advancing patient health outcomes through healthcare communications that improve the way patients and diseases are managed, and medicines are used. Lucid Group’s pioneering approaches have received industry-wide recognition and have consistently led to above industry growth.
With offices in the UK, US and Asia, Lucid now employs around 250 people. Lucid works in partnership with the world’s leading pharmaceutical and biotech organisations and has played a pivotal role in providing healthcare communication solutions for many of the industry’s innovative blockbuster assets.
Humatica was engaged by ICG to provide Organisational Due Diligence advice for this transaction.
Source: Private Equity Wire
